Study in Women With Advanced Breast Cancer Receiving Palbociclib With AI or Fulvestrant
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Hormone Receptor Positive Tumor|Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Interventions: DRUG: Palbociclib|DRUG: Letrozole|DRUG: Anastrozole|DRUG: Exemestane|DRUG: Fulvestrant
Sponsor: iOMEDICO AG
Collaborators: Pfizer